{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:36:45Z","timestamp":1794199005135,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210058, JP21fk0210065, JP21fk0210073, JP21fk0210090"],"award-info":[{"award-number":["JP21fk0210058, JP21fk0210065, JP21fk0210073, JP21fk0210090"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Reliable noninvasive predictors of the top three causes of death [cardiovascular diseases (CVDs), malignancies, and liver-related events in patients with non-alcoholic fatty liver disease (NAFLD)] have not yet been determined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively investigated the incidence of three complications [CVDs, malignancy (except for liver cancer), and liver-related events] in 477 Japanese patients with histo-pathologically confirmed NAFLD for a median follow-up of 5.9\u00a0years. In addition to histological findings, we also investigated noninvasive predictors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A score of\u2009\u2265\u20092.67 for the noninvasive diagnosis of stage 4 fibrosis based on the Fibrosis-4 (<jats:underline>FIB-4<\/jats:underline>) index indicated a high level area under the receiver operating characteristic (AUROC) curve (0.90), sensitivity (82.9%), specificity (86.4%), and negative predictive value [(NPV) of 98.5%]. The yearly incidence rates of CVDs, malignancies, and liver-related events were found to be 1.04%, 0.83%, and 0.30%, respectively. Multivariate analysis identified a <jats:underline>FIB-4<\/jats:underline> index\u2009\u2265\u20092.67 score as a significant and independent, noninvasive predictor of these three complications. Furthermore, the cumulative incidence rates of CVDs were significantly different among the three genotypes of <jats:italic>PNPLA3<\/jats:italic>. <jats:italic>PNPLA3<\/jats:italic> genotype CC, chronic kidney disease (CKD), and <jats:underline>FIB-4<\/jats:underline> index\u2009\u2265\u20092.67 was could be attributed to these three significant CVD risk factors. The rates of CVDs were significantly different among the three subgroups based on the combination of risk factors. In malignancy (except for liver cancer), the incidence rate of colon cancer was 25.0%; in particular, the rate in females was 53.8%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results highlighted the importance of the <jats:italic>PNPLA3<\/jats:italic> genotype and <jats:underline>FIB-4<\/jats:underline> index\u2009\u2265\u20092.67 on the incidence of complications in Japanese patients with NAFLD, especially the incidence of CVDs. Early diagnosis, based on the presence of one or more risk factors, and early treatment might improve the prognosis for NAFLD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-02020-z","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:02:41Z","timestamp":1637316161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD"],"prefix":"10.1186","volume":"21","author":[{"given":"Norio","family":"Akuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"2020_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"2020_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.21347","volume":"44","author":"R Williams","year":"2006","unstructured":"Williams R. Global changes in liver disease. Hepatology. 2006;44:521\u20136.","journal-title":"Hepatology"},{"key":"2020_CR3","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1053\/j.gastro.2008.02.077","volume":"134","author":"DM Torres","year":"2008","unstructured":"Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682\u201398.","journal-title":"Gastroenterology"},{"key":"2020_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.22603","volume":"49","author":"R Vuppalanchi","year":"2009","unstructured":"Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306\u201317.","journal-title":"Hepatology"},{"key":"2020_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475\u201385.","journal-title":"World J Gastroenterol"},{"key":"2020_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12876-018-0900-1","volume":"18","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol. 2018;18:165.","journal-title":"BMC Gastroenterol"},{"key":"2020_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0032-1306421","volume":"32","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3\u201313.","journal-title":"Semin Liver Dis"},{"key":"2020_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"2020_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/hep.24268","volume":"53","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874\u201382.","journal-title":"Hepatology"},{"key":"2020_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389\u201397.","journal-title":"Gastroenterology"},{"key":"2020_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"key":"2020_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","volume":"151","author":"DH Sinn","year":"2016","unstructured":"Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151:481\u20138.","journal-title":"Gastroenterology"},{"key":"2020_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"2020_CR14","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467\u201374.","journal-title":"Am J Gastroenterol"},{"key":"2020_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"2020_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02049-0","author":"K Nagai","year":"2021","unstructured":"Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2021. https:\/\/doi.org\/10.1007\/s10157-021-02049-0.","journal-title":"Clin Exp Nephrol"},{"key":"2020_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","volume":"68","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, Chang HS, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2018;68:140\u20136.","journal-title":"J Hepatol"},{"key":"2020_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322786","author":"TG Simon","year":"2020","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2020. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786.","journal-title":"Gut"},{"key":"2020_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","volume":"53","author":"H Ishiba","year":"2018","unstructured":"Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018;53:1216\u201324.","journal-title":"J Gastroenterol"},{"key":"2020_CR20","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","volume":"23","author":"C Pirazzi","year":"2014","unstructured":"Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23:4077\u201385.","journal-title":"Hum Mol Genet"},{"key":"2020_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2350-11-172","volume":"11","author":"K Hotta","year":"2010","unstructured":"Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet. 2010;11:172.","journal-title":"BMC Med Genet"},{"key":"2020_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","volume":"39","author":"BK Lauridsen","year":"2018","unstructured":"Lauridsen BK, Stender S, Kristensen TS, Kofoed KF, K\u00f8ber L, Nordestgaard BG, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J. 2018;39:385\u201393.","journal-title":"Eur Heart J"},{"key":"2020_CR23","doi-asserted-by":"publisher","first-page":"e13519","DOI":"10.1111\/eci.13519","volume":"51","author":"P Dongiovanni","year":"2021","unstructured":"Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: from epidemiology to drug approaches. Eur J Clin Invest. 2021;51:e13519.","journal-title":"Eur J Clin Invest"},{"key":"2020_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hepr.12840","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis\/fibrosis progression. Hepatol Res. 2017;47:1083\u201392.","journal-title":"Hepatol Res"},{"key":"2020_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02815-9","author":"MA Behairy","year":"2021","unstructured":"Behairy MA, Sherief AF, Hussein HA. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. Int Urol Nephrol. 2021. https:\/\/doi.org\/10.1007\/s11255-021-02815-9.","journal-title":"Int Urol Nephrol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02020-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:09:24Z","timestamp":1637316564000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02020-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Human Ethics Review Committee at Toranomon Hospital and each patient provided a signed informed consent at the time of liver histological diagnosis. The study was conducted in compliance with the International Conference on Harmonization guidelines for Good Clinical Practice (E6) and the 2013 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"(1) Hiromitsu Kumada has received honoraria from Gilead Sciences, AbbVie Inc., Eisai Co., Ltd, and Dainippon Sumitomo Pharma. (2) Yusuke Kawamura has received honoraria from Eisai Co., Ltd. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This paper has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}}],"article-number":"434"}}